"Golden Ticket" Contests

image

BioLabs@NYULangone Golden Tickets: New York City

B

ioLabs offers co-working spaces for life science start-ups where researchers can test, develop and grow ideas. The goal is to change how scientific entrepreneurs do business by building an ecosystem that empowers bio-innovators to grow quickly, while maximizing capital efficiency. 

Bristol-Myers Squibb partners with BioLabs@NYULangone, a co-working facility in Manhattan built to attract the best biotech companies in early-stage life sciences. BioLabs@NYULangone provides fully equipped, permitted and supported lab space for biomedical research, plus programming and unmatched networking opportunities to help start-ups advance their science and build their companies.

The Bristol-Myers Squibb Golden Ticket competition provides three separate opportunities for a startup business to secure a free lab bench at BioLabs@NYULangone for one year. 

Click here to learn more about BioLabs@NYULangone.
Click here to submit an application for a 2019 Golden Ticket
Click here for Program Rules

LabCentral Golden Tickets: Cambridge, Mass.

LabCentral is in Kendall Square, a biotech innovation hub in Cambridge, Mass. LabCentral is a shared laboratory space designed as a launch pad for high-potential life-sciences and biotech start-ups. It offers fully permitted laboratory and office space for as many as 60 startups comprising approximately 200 scientists and entrepreneurs. 

LabCentral provides fully equipped, permitted and supported lab space for biomedical research, plus programming and unmatched networking opportunities to help start-ups advance their science and build their companies.

Bristol-Myers Squibb is a platinum sponsor of LabCentral. Each year, Bristol-Myers Squibb sponsors a contest to award two “Golden Tickets”. Each Golden Ticket is one year of underwritten individual laboratory bench space at LabCentral ("Award").

Companies engaged in therapeutic research in the fields of oncology, hematology, immunoscience, cardiovascular disease or fibrotic diseases are encouraged to apply, as are those pursuing research in novel target identification, drug delivery, discovery technology platforms or translational R&D. 

Click here to read about our 2019 LabCentral Golden Ticket winners.

Click here to learn more about LabCentral.

Hear from past Bristol-Myers Squibb LabCentral Golden Ticket winners:

Jake Becraft, co-founder and CEO, Strand Therapeutics

Leila Pirhaji, founder and CEO, ReviveMed

Abdul Hakkim and Tobias Fuchs, co-founders, Neutrolis